iifl-logo

Venus Remedies Ltd Profit & Loss Statement

453.1
(0.11%)
Sep 15, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

FINANCIALS

Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

575.18

514.62

322.35

355.07

yoy growth (%)

11.76

59.64

-9.21

-5.42

Raw materials

-375.96

-336.68

-176.8

-205.42

As % of sales

65.36

65.42

54.84

57.85

Employee costs

-43.74

-35.88

-33.78

-27.82

As % of sales

7.6

6.97

10.48

7.83

Other costs

-86.64

-95.18

-68.69

-78.26

As % of sales (Other Cost)

15.06

18.49

21.31

22.04

Operating profit

68.82

46.86

43.06

43.56

OPM

11.96

9.1

13.35

12.26

Depreciation

-32.57

-34.28

-31.05

-32.72

Interest expense

0

-12.72

-13.04

-34.97

Other income

8.42

17.76

3.57

0.72

Profit before tax

44.67

17.61

2.54

-23.42

Taxes

4.31

13.21

-1.96

-3.16

Tax rate

9.66

74.98

-77.04

13.49

Minorities and other

0

0

0

0

Adj. profit

48.98

30.83

0.58

-26.58

Exceptional items

0

23.44

-8.81

0

Net profit

48.98

54.27

-8.22

-26.58

yoy growth (%)

-9.73

-759.69

-69.05

31.32

NPM

8.51

10.54

-2.55

-7.48

Venus Remedies : related Articles

Venus Remedies Secures Ukrainian GMP Certification for Baddi Facility

The Unit-II Baddi plant, which got the renewed certification, has state-of-art infrastructure and state-of-the-art manufacturing technology to cater to complex therapeutic segments in an efficient manner. 

22 May 2025|12:41 PM
Read More
Venus Remedies Secures Key Approvals, Strengthens Global Market Reach

The company is now set to further expand into Eastern Europe as this recognition ensures patients and healthcare providers have access to reliable and effective antibiotics.

31 Dec 2024|09:16 PM
Read More
Venus Remedies gets approval for pre-filled syringe facility

Furthermore, the NPRA's recognition will enable Venus Remedies to capitalise on the expanding global demand for enoxaparin.

6 Nov 2024|10:36 AM
Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.